Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pulmonary Therapy
Published in: Pulmonary Therapy 1/2017

Open Access 01-06-2017 | Review

A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma

Authors: Qian Ye, Xiao-Ou He, Anthony D’Urzo

Published in: Pulmonary Therapy | Issue 1/2017

Login to get access

Abstract

Asthma is a chronic inflammatory disease characterized by symptoms of cough, dyspnea, chest tightness, and wheeze. Inhaled corticosteroids (ICS) have been recommended as initial therapy in the treatment of persistent asthma in all guidelines, as they have been shown to reduce morbidity and mortality. However, high-dose regimens and long-term use of ICS may be associated with a variety of side effects, similar to those observed with systemic corticosteroid therapy. These side effects include impaired growth in children, osteoporosis, fractures, glaucoma, cataracts, and skin thinning. The current recommendations on ICS use in asthma management will be reviewed in this article with a view to highlight treatment strategies that strike an optimal balance between safety and efficacy.
Literature
1.
Myers TR. Guidelines for asthma management: a review and comparison of 5 current guidelines. Respir Care. 2008;53(6):751–67.PubMed
2.
Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA. 1992;268:3462–4.PubMedCrossRef
3.
Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887–91.PubMedCrossRef
4.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Eng J Med. 2000;343(5):332–6.CrossRef
5.
Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther. 2007;20:23–5.PubMedCrossRef
6.
Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 2006;100(8):1307–17.PubMedCrossRef
7.
8.
9.
Johansson AK, Sergejeva S, Sjostrand M, Lee JJ, Lotvall J. Allergen-induced traffic of bone marrow eosinophils, neutrophils and lymphocytes to airways. Eur J Immunol. 2004;34:3135–45.PubMedCrossRef
10.
11.
Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773–86 (quiz 787-8, Epub 2006 Sep 1).PubMedCrossRef
12.
Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368(9537):780–93.PubMedCrossRef
13.
Lemanski RF. Issues in understanding pediatric asthma: epidemiology and genetics. J Allergy Clin Immunol. 2002;109(6 Suppl):S521–4.CrossRef
14.
Barnes PJ. Review inhaled corticosteroids. Pharmaceuticals (Basel). 2010;3(3):514–40.CrossRef
15.
Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des. 2004;10:2807–16.PubMedCrossRef
16.
Mak JCW, Nishikawa M, Barnes PJ. Glucocorticoids increase β2-adrenergic receptor transcription in human lung. Am J Physiol. 1995;12:L41–6.
17.
Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce β2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med. 1997;155:704–10.PubMedCrossRef
18.
Ito J, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. New Engl J Med. 2005;352:1967–76.PubMedCrossRef
19.
Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med. 2006;174:134–41.PubMedPubMedCentralCrossRef
20.
Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Ann Rev Physiol. 2009;71:451–64.CrossRef
21.
Derendorf H. Pharmacokinetic and pharmacodynamics properties of inhaled ciclesonide. J Clin Pharmacol. 2007;47(6):782–9.PubMedCrossRef
22.
Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–50.PubMedCrossRef
23.
Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin N Am. 2005;25(3):469–88.CrossRef
24.
Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91:326–34.PubMedCrossRef
25.
Sobande PO, Kercsmar CM. Inhaled corticosteroids in asthma management. Respir Care. 2008;53(5):625–33.PubMed
26.
27.
Kelly HW. Comparison of inhaled corticosteroids: an update. Annu Pharmacother. 2009;43(3):519–27.CrossRef
28.
Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs. 2008;68:1741–70.PubMedCrossRef
29.
Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61:1325–50.PubMedCrossRef
30.
Edsbacker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol. 2002;88:609–16.PubMedCrossRef
31.
Miller-Larsson A, Mattsson H, Hjertberg E, Dahlback M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998;26:623–30.PubMed
32.
Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18:390–6.PubMedCrossRef
33.
Mukker JK, Singh RSP, Derendorf H. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. J Pharm Sci. 2016;105:2509–14.PubMedCrossRef
34.
Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410–8.PubMedCrossRef
35.
Wells KE, Peterson EL, Ahmedani BK, Williams LK. Real world effects of once vs. greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol. 2013;111(3):216–20.PubMedPubMedCentralCrossRef
36.
Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–91.PubMedPubMedCentralCrossRef
37.
Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. 2012:CD009611. doi:10.1002/14651858CD009611.pub2.
38.
Dolovich MA, MacIntyre NR, Dhand R, Gross NJ, Hess, Pierson DJ. Consensus conference on aerosols and delivery devices. Respir Care. 2000;45:588–776.
39.
Dekhuijzen PNR, Lavorini F, Usmani OS. Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat ® or HandiHaler®. Dovepress. 2016;10:1561–72.
40.
41.
Lavorini F, Fontana GA, Usmani OS. New inhaler devices—the good, the bad and the ugly. Respiration. 2014;88(1):3–15.PubMedCrossRef
42.
Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose–response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther. 2002;24:1–20.PubMedCrossRef
43.
Dahl R, Lundback B, Malo JL, International Study Group, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest. 1993;104:1352–8.PubMedCrossRef
44.
Gaddie J, Reid IW, Skinner C, Petrie GR, Sinclair DJ, Palmer KN. Aerosol beclomethasone dipropionate: a dose–response study in chronic bronchial asthma. Lancet. 1973;ii:280–1.CrossRef
45.
Welch M, Bernstein D, Gross G, Kane RE, Banerji D, Azmacort HFA Study Group. A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Chest. 1999;116:1304–12.PubMedCrossRef
46.
Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2000;106:485–92.PubMedCrossRef
47.
Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998;101(4 Pt 1):457–63.PubMedCrossRef
48.
Currie GP, Fowler SJ, Lipworth BJ. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann Allergy Asthma Immunol. 2003;90:194–8.PubMedCrossRef
49.
Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin Immunol. 2000;105:752–9.PubMedCrossRef
50.
Jatakanon A, Lim S, Chung KF, Barnes PJ. An inhaled steroid improves markers of airway inflammation in patients with mild asthma. Eur Respir J. 1998;12:1084–8.PubMedCrossRef
51.
Hojo M, Kudo K. Dose–response relationship for inhaled corticosteroids and the add-on effect of long-acting β2-adrenergic receptor agonists in adult chronic asthmatics. Allergol Int. 2004;43:291–9.CrossRef
52.
Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(Suppl):1–34.PubMedCrossRef
53.
Kelly HW. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003;112:469–78.PubMedCrossRef
54.
Pauwels RA, Lofdahl CG, Postma DS, Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337-1405-11.
55.
Rank MA, Peters SP. The risks, benefits, and uncertainties of stepping down asthma medications. J Allergy Clin Immunol Pract. 2014;2(5):503–9.PubMedCrossRef
56.
57.
Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomized, double-blind, placebo-controlled trial. Lancet. 2011;377:650–7.PubMedPubMedCentralCrossRef
58.
Juniper EF, Kline PA, Vanzieleghem MA, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol. 1991;87:483–9.PubMedCrossRef
59.
ZuWallack RL, Rosen JP, Cohen L, et al. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. J Allergy Clin Immunol. 1997;99:278–85.PubMedCrossRef
60.
Visser ML, Postma DS, Arends LR, de Vries TW, Duiverman EJ, Brand PL. One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Am J Respir Crit Care Med. 2001;164:2073–7.PubMedCrossRef
61.
Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: a randomized controlled trial. BMJ. 2003;326:1115.PubMedPubMedCentralCrossRef
62.
Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356:2040–52.PubMedCrossRef
63.
American Lung Association Asthma Clinical Research Network. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007;356:2027–39.CrossRef
64.
Tonelli M, Bacci E, Dente FL, et al. Predictors of symptom recurrence after lose-dose inhaled corticosteroid cessation in mild persistent asthma. Respir Med. 2006;100:622–9.PubMedCrossRef
65.
Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, Koskela H, Brannan JD, Freed R, Andersson M, Chan HK, Woolcock AJ. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163:406–12.PubMedCrossRef
66.
Belda J, Parameswaran K, Lemiere C, Kamada D, O’Byrne PM, Hargreave FE. Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Resp J. 2006;13:129–33.
67.
Tsurikisawa N, Oshikata C, Tsuburai T, et al. Markers for step-down of inhaled corticosteroid therapy in adult asthmatics. Allergol Int. 2012;61:419–29.PubMedCrossRef
68.
Rank MA, Branda ME, McWilliams DB, et al. Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program. Ann Allergy Asthma Immunol. 2013;110:354–8.PubMedCrossRef
69.
Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med. 2005;171:1077–82.PubMedCrossRef
70.
Hoffmann HJ, Nielsen LP, Harving H, Heinig JH, Dahl R. Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11. Clin Respir J. 2008;2:149–57.PubMedCrossRef
71.
Baba K, Sakakibara A, Yagi T, Niwa S, Wakayama H, Takagi K. Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein. Respirology. 2002;7:255–66.PubMedCrossRef
72.
Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998;53:91–5.PubMedPubMedCentralCrossRef
73.
Berlyne GS, Parameswaran K, Kamada D, Efthimiadis A, Hargreave FE. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J Allergy Clin Immunol. 2000;106:638–44.PubMedCrossRef
74.
Mehta V, Stokes JR, Berro A, Romero FA, Casale TB. Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma. Ann Allergy Asthma Immunol. 2009;103:31–7.PubMedCrossRef
75.
Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163–73.PubMedCrossRef
76.
Greening AP, Ind PW, Northfield M, Shaw G, Allen & Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219–24.PubMedCrossRef
77.
Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368–73.PubMedPubMedCentralCrossRef
78.
Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. N Engl J Med. 2016;375(9):850–60.PubMedCrossRef
79.
Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374(19):1822–30.PubMedCrossRef
80.
Castle W, Fuller R, Hall J, Palmer J. Serevent Nationwide Surveillance Study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034–7.PubMedPubMedCentralCrossRef
81.
Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.PubMedCrossRef
82.
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170:836–44.PubMedCrossRef
83.
O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392–7.PubMedCrossRef
84.
O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–36.PubMedCrossRef
85.
Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129:246–56.PubMedCrossRef
86.
Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20:1403–18.PubMedCrossRef
87.
88.
89.
Mori K, Fujisawa T, Inui N, et al. Step-down treatment from medium-dosage of budesonide/formoterol in controlled asthma. Respir Med. 2016;119:1–6.PubMedCrossRef
90.
Bozek JL, Kraft M, Krishnan JA, et al. Long-acting beta-agonist step-off in patients with controlled asthma. Arch Intern Med. 2012;172(18):1365–75.CrossRef
91.
Allen DB, Leonard B, Hartmut D, Robert D, Gene LC, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(3 Suppl):S1–40.PubMedCrossRef
92.
Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomized crossover study. Lancet. 2000;356:556–61.PubMedCrossRef
93.
Weiner P, Berar-Yanay N, Davidovich A, Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest. 1999;116:931–4.PubMedCrossRef
94.
Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(Suppl 39):1–34.PubMedCrossRef
95.
Salvatoni A, Piantanida E, Nosetti L, Nespoli L. Inhaled corticosteroids in childhood asthma: long-term effects on growth and adrenocortical function. Paediatr Drugs. 2003;5:351–61.PubMedCrossRef
96.
Meibohm B, Hochhaus G, Rohatagi S, et al. Dependency of cortisol suppression on the administration time of inhaled corticosteroids [published correction appears in J Clin Pharmacol. 1997;37:1000]. J Clin Pharmacol. 1997;37:704–10.PubMedCrossRef
97.
98.
Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the UK. Arch Dis Child. 2002;87:457–61.PubMedPubMedCentralCrossRef
99.
Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165(10):1377–83.PubMedCrossRef
100.
Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systemic review and meta-analysis. Arch Intern Med. 1999;159:941–55.PubMedCrossRef
101.
Wolthers OB, Hansen M, Juul A, Nielsen NK, Pedersen S. Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Pediatr Res. 1997;41:44–50.PubMedCrossRef
102.
Kannisto S, Korppi M, Remes K, Voutilainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab. 2000;85:652–7.PubMed
103.
Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med. 1998;92:95–104.PubMedCrossRef
104.
The Childhood Asthma Management Program. (CAMP) Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–63.CrossRef
105.
Silverstein MD, Yunginger JW, Reed CE, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol. 1997;99:466–74.PubMedCrossRef
106.
Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064–9.PubMedCrossRef
107.
Guilbert TW, Morgan WJ, Krawiec M, et al. The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education Network. Control Clin Trials. 2004;25(3):286–310.PubMedCrossRef
108.
109.
110.
Hopp RJ, Degan JA, Phelan J, Lappe J, Gallagher GC. Cross-sectional study of bone density in asthmatic children. Pediatr Pulmonol. 1995;20:189–92.PubMedCrossRef
111.
Gregson RK, Rao R, Murrills AJ, Taylor PA, Warner JO. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporos Int. 1998;8:418–22.PubMedCrossRef
112.
Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics. 2004;114(2):469–73.PubMedCrossRef
113.
Monadi M, Javadian Y, Cheraghi M, Heidari B, Amiri M. Impact of treatment with inhaled corticosteroids on bone mineral density of patients with asthma: related with age. Osteoporos Int. 2015;262:2013–8.CrossRef
114.
Richy F, Bousquet J, Ehrlich GE, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int. 2003;14(3):179–90 (Epub).PubMedCrossRef
115.
Laatikainen AK, Kroger HP, Tukiainen HO, Honkanen RJ, Saarikoski SV. Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1179–85.PubMedCrossRef
116.
Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;105(6):1722–7.PubMedCrossRef
117.
118.
Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet. 2000;355:1399–403.PubMedCrossRef
119.
Matsumoto H, Ishihara K, Hasegawa T, Umeda B, Niimi A, Hino M. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest. 2001;120(5):1468–73.PubMedCrossRef
120.
Wheelock C, St Anna L. Clinical inquiry. Do inhaled steroids reduce bone mineral density and increase fracture risk? J Fam Pract. 2012;61(8):493–508.PubMed
121.
Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomized to treatment inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax. 2001;56(4):272–8.PubMedPubMedCentralCrossRef
122.
Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;1:CD003537.
123.
124.
Bahceciler NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J. 2000;19:215–8.PubMedCrossRef
125.
Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219–29.PubMedCrossRef
126.
Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:189–95.PubMedPubMedCentralCrossRef
127.
128.
Eurich DT, Lee C, Marrie TJ, Majumdar SR. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis. 2013;57:1138–44.PubMedCrossRef
129.
McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case–control study. Chest. 2013;144:1788–94.PubMedCrossRef
130.
Weatherall M, James K, Clay J, et al. Dose–response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38:1451–8.PubMedCrossRef
131.
Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risk of ocular hypertension or open-angle glaucoma. JAMA. 1997;277:722–7.PubMedCrossRef
132.
Samily N, Walton DS, Dreyer EB. Inhaled steroids: effect on intraocular pressure in patients without glaucoma. Can J Ophthalmol. 1996;31(3):120–3.
133.
Pelkonen A, Kari O, Selroos O, Nikander K, Haahtela T, Turpeinen M. Ophthalmologic findings in children with asthma receiving inhaled budesonide. J Allergy Clin Immunol. 2008;122(4):832–4.PubMedCrossRef
134.
Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ. 1990;300:1548–51.PubMedPubMedCentralCrossRef
135.
Mak VHF, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. Eur Resp J. 1992;5:1066–74.
136.
Roy A, Leblanc C, Paquette L, Ghezzo H, Cote J, Cartier A, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency an association with adrenal function. Eur Respir J. 1996;9:226–31.PubMedCrossRef
137.
Autio P, Karjalainen J, Risteli L, Kiistala U, Oikarinen A. Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Am J Respir Crit Care Med. 1996;153:1172–5.PubMedCrossRef
138.
Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340:1948–53.PubMedCrossRef
139.
Tashkin DP, Murray HE, Skeans M, Murray RP. Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest. 2004;126:1123–33.PubMedCrossRef
140.
Daley-Yates PT. Pharmacological aspects of glucocorticoid therapy. In: Wolthers OD, editor. Exogenous glucocorticoids in paediatric asthma. Kerala: Transworld Research Network; 2007. p. 1–18.
141.
Daley-Yates PT, Harker AJ, Taylor S, Daniel MJ. Plasma protein binding of inhaled corticosteroids: reappraisal of its significance in systemic pharmacological activity. J Allergy Clin Immunol. 2005;115:S4.CrossRef
142.
Wolthers OD, Daley-Yates PT. Exogenous glucocorticoids in Paediatric asthma. In: Wolthers OD, editor. Inhaled glucocorticoids and hypothalamic–pituitary–adrenal axis function. Kerala: Transworld Research Network; 2007. p. 19–34.
143.
Daley-Yates PT, Pierre LN. A physiologically based pharmacokinetic/pharmacodynamic model predicting cortisol suppression for inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163:A518.
144.
Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of fluticasone propionate and mometosone furoate. Clin Ther. 2001;23:1339–54.PubMedCrossRef
145.
Daley-Yates PT, Derks MGM, Weeks AT, Mehta RS, Beerahee M, Sousa A. Pharmacokinetics and pharmacodynamics of fluticasone propionate and mometasone furoate dry powder inhalers in healthy and asthmatic subjects. Am J Respir Crit Care Med. 2005;2:A354.
146.
147.
Hogger P, Rohdewald P. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother. 1998;9:501–22.
148.
Daley-Yates PT, Kunka RL, Shen YY, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol. 2004;60:265–8.PubMedCrossRef
149.
Falcoz C, Oliver R, McDowall J, Ventresca GP, Bye A, Daley-Yates PT. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39(Suppl. 1):9–15.PubMedCrossRef
150.
Taylor S, Harker A. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal. 2006;41:299–303.PubMedCrossRef
151.
Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Bart J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S440–6.PubMedCrossRef
152.
Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin Ther. 2006;28:319–31.PubMedCrossRef
153.
Mager DE, Jusko WJ. Quantitative structure–pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci. 2001;91:2442–51.
154.
Agertoft L, Pedersen S. Lung deposition and systemic bioavailability of fluticasone Diskus and budesonide Turbuhaler. Am J Respir Crit Care Med. 2003;168:779–82.PubMedCrossRef
155.
Mackie AE, McDowall JE, Falcoz C, Ventresca GP, Bye A, Daley-Yates PT. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy subjects. Clin Pharmacokinet. 2000;39(1):23–30.PubMedCrossRef
156.
Thorsson L, Edsbacker S, Conradson TB. Lung deposition from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur Respir J. 1994;7:1839–44.PubMedCrossRef
157.
Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulized budesonide in pre-school children with asthma. Arch Dis Child. 1999;80:241–7.PubMedPubMedCentralCrossRef
158.
Jeal W, Faulds D. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs. 1997;53:257–80.PubMedCrossRef
159.
Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Sourgens H, Erdmann M. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol. 1995;35:302–5.PubMedCrossRef
160.
Barth J, Damoiseaux M, Möllmann H, Brandis KH, Hochhaus G, Derendorf H. Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol. 1992;30:317–24.PubMed
161.
162.
Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1:356–63.PubMedCrossRef
163.
Hübner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin N Am. 2005;25:469–88.CrossRef
164.
Derendorf H, Nave R, Drollman A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28:1042–50.PubMedCrossRef
Metadata
Title
A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma
Authors
Qian Ye
Xiao-Ou He
Anthony D’Urzo
Publication date
01-06-2017
Publisher
Springer Healthcare
Published in
Pulmonary Therapy / Issue 1/2017
Print ISSN: 2364-1754
Electronic ISSN: 2364-1746
DOI
https://doi.org/10.1007/s41030-017-0043-5

Other articles of this Issue 1/2017

Pulmonary Therapy 1/2017 Go to the issue

Original Research

Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma

Original Research

Aerosol Deposition of Inhaled Corticosteroids/Long-Acting β2-Agonists in the Peripheral Airways of Patients with Asthma Using Functional Respiratory Imaging, a Novel Imaging Technology

Review

3D Printing and Personalized Airway Stents

Original Research

Effect of Nebulizer Designs on Aerosol Delivery During Non-Invasive Mechanical Ventilation: A Modeling Study of In Vitro Data

Review

Riociguat in PAH and CTEPH: Strategies for Patient Management

Review

The Respimat® Development Story: Patient-Centered Innovation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits